Brought to you by 
Merck pays $50mm cash up front in new viral disease mRNA deal with Moderna; Agreement Cancelled
08 Oct 2020
Executive Summary
Merck & Co. Inc. is entering the messenger-RNA space through a new deal with Moderna Therapeutics LLC aimed at turning out vaccines and passive immunity therapies against viral diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com